• AAPL 195.71
  • TSLA 243.84
  • AMZN 147.42
  • BTC-USD 44174.207
  • ETH-USD 2353.7188
  • EURUSD 1.0764
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. NSTM.US

Hollywood Media Co (NSTM PINK) stock market data APIs

$0.08 0(0%) as of December 7, 2023

Hollywood Media Co Financial Data Overview

0.08
0.08
-
0.08
0.08
0.08-0.28
3 751 K
46 882 K
425 K
-0.0234
0.0181
0.382
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NSTM',
Type: 'Common Stock',
Name: 'Hollywood Media Co',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BDL4C3',
ISIN: NULL,
CUSIP: NULL,
CIK: '912544',
EmployerIdNumber: '65-0385686',
FiscalYearEnd: 'December',
IPODate: '1993-11-12',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Hollywood Media Co Fundamental Data is available in our Financial Data APIs

  • Net Revenue 425 K
  • EBITDA -4 808 822
  • Earnings Per Share -0.1
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Hollywood Media Co Earnings via APIs

  • Latest Release 2023-11-01
  • EPS/Forecast 0

Get Hollywood Media Co End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Hollywood Media Co latest news via APIs

NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares

BOCA RATON, Fla. and JERUSALEM, Dec. 01, 2020 (GLOBE NEWSWIRE) -- NovelStem International Corp.(OTC Pink: NSTM), a biotechnology company focused on its stem cell-based technology platform, developed...
  • BIOTECHNOLOGY
  • CANCER TREATMENT
  • CHEMOTHERAPY RESISTANCE
  • DIAGNOSTICS
  • GENETICS
  • NOVELSTEM INTERNATIONAL CORP
  • OTC MARKETS:NSTM

NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance; Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments

Screening of resistance diagnostics completed for twelve standard-of-care cancer treatments representing a significant portion of cancer treatment protocols. COVID-19 research collaboration initiated ...
  • BIOTECH
  • CANCER TREATMENT
  • CHEMOTHERAPY RESISTANCE
  • DIAGNOSTIC
  • GENETICS
  • NOVELSTEM INTERNATIONAL CORP
  • OTC MARKETS:NSTM
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com